Related Experiment Videos
Effect of recombinant human granulocyte-colony-stimulating factor on renal scarring following infection with
M Haraoka1, T Matsumoto, Y Mizunoe
1Department of Urology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
Abstract:
Renal scars have been thought to occur only in later stages of chronic pyelonephritis. In our experimental pyelonephritis model, bacteria with mannose-sensitive (MS) pili on its surface promoted renal scarring when inoculated into renal parenchyma. Pretreatment with recombinant human granulocyte-colony-stimulating factor (rhGCSF) inhibited the renal scarring which followed inoculation with MS-piliated bacteria, whereas posttreatment at an early stage of infection had no effect on renal scarring. These findings suggest that rhGCSF may be useful for the prevention of infection without increasing the tissue damage to the renal parenchyma which leads to the renal scarring. Even when rhGCSF is used for treatment of kidney infection, it does not promote increased renal scarring through the increased invasion of leukocytes at the inflammatory site.
Insights
Recombinant human granulocyte-colony-stimulating factor (rhG-CSF) prevents kidney scarring from bacterial infections when given before exposure. Early infection treatment with rhG-CSF did not affect scarring, suggesting a preventative role.
Area of Science:
- Nephrology
- Immunology
- Microbiology
Background:
- Renal scarring is typically associated with advanced chronic pyelonephritis.
- Bacteria possessing mannose-sensitive (MS) pili can induce renal scarring in experimental models.
Purpose of the Study:
- To investigate the potential of recombinant human granulocyte-colony-stimulating factor (rhG-CSF) in preventing renal scarring.
- To evaluate the effect of rhG-CSF on infection-induced renal tissue damage.
Main Methods:
- An experimental pyelonephritis model was established using MS-piliated bacteria.
- rhG-CSF was administered as a pretreatment or early-stage posttreatment.
- Renal scarring and leukocyte infiltration were assessed.
Main Results:
- Pretreatment with rhG-CSF significantly inhibited renal scarring caused by MS-piliated bacteria.
- Posttreatment with rhG-CSF at an early infection stage did not affect renal scarring.
- rhG-CSF did not increase renal scarring by promoting leukocyte invasion.
Conclusions:
- rhG-CSF shows promise for preventing renal scarring associated with bacterial kidney infections.
- rhG-CSF may be a valuable tool for managing kidney infections without exacerbating tissue damage.